|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPS18B |
Gene summary for MRPS18B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPS18B | Gene ID | 28973 |
| Gene name | mitochondrial ribosomal protein S18B | |
| Gene Alias | C6orf14 | |
| Cytomap | 6p21.33 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | B0S7P4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 28973 | MRPS18B | cirrhotic3 | Human | Liver | Cirrhotic | 6.02e-13 | 1.75e-01 | 0.0215 |
| 28973 | MRPS18B | HCC1 | Human | Liver | HCC | 1.95e-15 | 5.61e+00 | 0.5336 |
| 28973 | MRPS18B | HCC2 | Human | Liver | HCC | 4.01e-20 | 5.09e+00 | 0.5341 |
| 28973 | MRPS18B | Pt13.a | Human | Liver | HCC | 7.44e-05 | 3.07e-01 | 0.021 |
| 28973 | MRPS18B | Pt13.b | Human | Liver | HCC | 3.63e-35 | 5.02e-01 | 0.0251 |
| 28973 | MRPS18B | Pt14.b | Human | Liver | HCC | 7.94e-08 | 3.28e-01 | 0.018 |
| 28973 | MRPS18B | S014 | Human | Liver | HCC | 4.08e-29 | 1.49e+00 | 0.2254 |
| 28973 | MRPS18B | S015 | Human | Liver | HCC | 1.28e-23 | 1.66e+00 | 0.2375 |
| 28973 | MRPS18B | S016 | Human | Liver | HCC | 2.07e-27 | 1.49e+00 | 0.2243 |
| 28973 | MRPS18B | S027 | Human | Liver | HCC | 6.58e-03 | 8.07e-01 | 0.2446 |
| 28973 | MRPS18B | S028 | Human | Liver | HCC | 1.71e-16 | 1.20e+00 | 0.2503 |
| 28973 | MRPS18B | S029 | Human | Liver | HCC | 2.22e-14 | 1.29e+00 | 0.2581 |
| 28973 | MRPS18B | C04 | Human | Oral cavity | OSCC | 3.63e-25 | 1.66e+00 | 0.2633 |
| 28973 | MRPS18B | C21 | Human | Oral cavity | OSCC | 9.86e-58 | 2.13e+00 | 0.2678 |
| 28973 | MRPS18B | C30 | Human | Oral cavity | OSCC | 1.05e-47 | 2.57e+00 | 0.3055 |
| 28973 | MRPS18B | C38 | Human | Oral cavity | OSCC | 2.76e-19 | 1.80e+00 | 0.172 |
| 28973 | MRPS18B | C43 | Human | Oral cavity | OSCC | 5.10e-15 | 4.80e-01 | 0.1704 |
| 28973 | MRPS18B | C46 | Human | Oral cavity | OSCC | 3.99e-47 | 1.18e+00 | 0.1673 |
| 28973 | MRPS18B | C51 | Human | Oral cavity | OSCC | 5.96e-14 | 1.16e+00 | 0.2674 |
| 28973 | MRPS18B | C57 | Human | Oral cavity | OSCC | 2.14e-13 | 7.83e-01 | 0.1679 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:014005313 | Esophagus | ESCC | mitochondrial gene expression | 93/8552 | 108/18723 | 1.96e-18 | 2.03e-16 | 93 |
| GO:003254314 | Esophagus | ESCC | mitochondrial translation | 68/8552 | 76/18723 | 1.02e-15 | 6.86e-14 | 68 |
| GO:0032543 | Liver | Cirrhotic | mitochondrial translation | 40/4634 | 76/18723 | 1.61e-07 | 4.29e-06 | 40 |
| GO:0140053 | Liver | Cirrhotic | mitochondrial gene expression | 49/4634 | 108/18723 | 2.35e-06 | 4.31e-05 | 49 |
| GO:01400531 | Liver | HCC | mitochondrial gene expression | 82/7958 | 108/18723 | 1.49e-12 | 7.20e-11 | 82 |
| GO:00325431 | Liver | HCC | mitochondrial translation | 62/7958 | 76/18723 | 2.95e-12 | 1.34e-10 | 62 |
| GO:01400533 | Oral cavity | OSCC | mitochondrial gene expression | 78/7305 | 108/18723 | 2.37e-12 | 9.86e-11 | 78 |
| GO:00325434 | Oral cavity | OSCC | mitochondrial translation | 59/7305 | 76/18723 | 7.21e-12 | 2.70e-10 | 59 |
| GO:003254313 | Oral cavity | LP | mitochondrial translation | 43/4623 | 76/18723 | 2.85e-09 | 1.26e-07 | 43 |
| GO:014005312 | Oral cavity | LP | mitochondrial gene expression | 53/4623 | 108/18723 | 3.54e-08 | 1.27e-06 | 53 |
| GO:00325436 | Skin | cSCC | mitochondrial translation | 47/4864 | 76/18723 | 4.70e-11 | 2.22e-09 | 47 |
| GO:01400535 | Skin | cSCC | mitochondrial gene expression | 56/4864 | 108/18723 | 8.06e-09 | 2.56e-07 | 56 |
| GO:01400536 | Thyroid | PTC | mitochondrial gene expression | 51/5968 | 108/18723 | 6.04e-04 | 3.83e-03 | 51 |
| GO:00325437 | Thyroid | PTC | mitochondrial translation | 38/5968 | 76/18723 | 7.52e-04 | 4.67e-03 | 38 |
| GO:014005314 | Thyroid | ATC | mitochondrial gene expression | 51/6293 | 108/18723 | 2.26e-03 | 1.06e-02 | 51 |
| GO:003254315 | Thyroid | ATC | mitochondrial translation | 38/6293 | 76/18723 | 2.26e-03 | 1.06e-02 | 38 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0520325 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
| hsa0520335 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
| hsa05203 | Liver | Cirrhotic | Viral carcinogenesis | 76/2530 | 204/8465 | 1.34e-02 | 4.20e-02 | 2.59e-02 | 76 |
| hsa052031 | Liver | Cirrhotic | Viral carcinogenesis | 76/2530 | 204/8465 | 1.34e-02 | 4.20e-02 | 2.59e-02 | 76 |
| hsa052032 | Liver | HCC | Viral carcinogenesis | 117/4020 | 204/8465 | 2.68e-03 | 8.98e-03 | 5.00e-03 | 117 |
| hsa052033 | Liver | HCC | Viral carcinogenesis | 117/4020 | 204/8465 | 2.68e-03 | 8.98e-03 | 5.00e-03 | 117 |
| hsa052038 | Oral cavity | OSCC | Viral carcinogenesis | 124/3704 | 204/8465 | 5.57e-07 | 3.28e-06 | 1.67e-06 | 124 |
| hsa0520314 | Oral cavity | OSCC | Viral carcinogenesis | 124/3704 | 204/8465 | 5.57e-07 | 3.28e-06 | 1.67e-06 | 124 |
| hsa0520324 | Oral cavity | LP | Viral carcinogenesis | 90/2418 | 204/8465 | 1.20e-06 | 1.38e-05 | 8.89e-06 | 90 |
| hsa0520334 | Oral cavity | LP | Viral carcinogenesis | 90/2418 | 204/8465 | 1.20e-06 | 1.38e-05 | 8.89e-06 | 90 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPS18B | SNV | Missense_Mutation | rs763959905 | c.265N>T | p.Arg89Trp | p.R89W | Q9Y676 | protein_coding | deleterious(0) | possibly_damaging(0.849) | TCGA-A1-A0SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPS18B | SNV | Missense_Mutation | novel | c.328G>A | p.Asp110Asn | p.D110N | Q9Y676 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| MRPS18B | SNV | Missense_Mutation | novel | c.178N>A | p.Glu60Lys | p.E60K | Q9Y676 | protein_coding | tolerated(0.33) | benign(0.115) | TCGA-GM-A3NW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
| MRPS18B | SNV | Missense_Mutation | c.73N>A | p.Val25Ile | p.V25I | Q9Y676 | protein_coding | tolerated(0.07) | benign(0.251) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| MRPS18B | SNV | Missense_Mutation | c.589G>C | p.Asp197His | p.D197H | Q9Y676 | protein_coding | tolerated(0.05) | benign(0.417) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MRPS18B | SNV | Missense_Mutation | novel | c.632N>A | p.Arg211Lys | p.R211K | Q9Y676 | protein_coding | tolerated(0.41) | benign(0.056) | TCGA-VS-A8QA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPS18B | SNV | Missense_Mutation | rs140805833 | c.212N>A | p.Arg71His | p.R71H | Q9Y676 | protein_coding | tolerated(0.1) | possibly_damaging(0.456) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPS18B | SNV | Missense_Mutation | novel | c.106N>T | p.Ala36Ser | p.A36S | Q9Y676 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| MRPS18B | SNV | Missense_Mutation | rs144633864 | c.644N>A | p.Arg215His | p.R215H | Q9Y676 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| MRPS18B | SNV | Missense_Mutation | c.346G>C | p.Asp116His | p.D116H | Q9Y676 | protein_coding | tolerated(0.3) | probably_damaging(1) | TCGA-AP-A0LF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |